Representatives from the US Food and Drug Administration, the US Centers for Disease Control and Prevention, the World Health Organization, the Southern African HIV Clinicians Society, the British HIV Association and the British Association for Sexual Health and Gilead Sciences will discuss various guidelines on the use of and FDA approval of daily TDF/FTC as PrEP.
This webinar will familiarize advocates with the types of regulatory and normative guidance documents that exist on PrEP—what they say, who they affect and what they may mean for policy and programming in various countries.